This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
About Koneksa Koneksa is a healthcaretechnology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drugdevelopment and market strategy. These adverse events often lead to hospitalizations and treatment interruptions that can reduce treatment efficacy.
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drugdevelopment. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drugdevelopment.
The utilization of evidence-based digital biomarkers is the key to transforming healthcare,” said Chris Benko, CEO, Koneksa. “We’re We’re on a mission to revolutionize drugdevelopment in clinical trials by harnessing the power of our digital solutions with real-time, data-driven insights.
These individuals have personally built leading technology platforms supercharging drugdevelopment globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,
By embracing technological advancements, focusing on personalised medicine, and addressing the challenges of chronic wounds, the industry can improve patient outcomes, reduce costs, and enhance the overall quality of care. HealthcareTechnology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content